The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders

Abstract

Parkinson's Disease (PD) and the closely related Dementia with Lewy Bodies (DLB) are due to the accumulation of pathogenic alpha-synuclein protein in brain cells manifest by heterogeneous motor and non-motor symptoms, including cognitive impairment and dementia. The majority of patients with Parkinson's Disease develop Dementia (PDD) in late stages of the disease and have widespread neocortical distribution of alpha-synuclein pathology at autopsy, compared with PD without dementia, in which neocortical synuclein pathology is less prevalent. These three entities PD, DLB and PDD comprise a clinical spectrum, collectively known as Lewy Body Disorders (LBD). Recent investigations into the neuropathological basis of LBD have demonstrated that while synuclein pathology is the defining feature of these disorders, it is often accompanied by other age-related neurodegenerative pathologies. In particular, amyloid plaque and tau tangle pathology characteristic of Alzheimer's Disease (AD) (~50% of all LBD patients have sufficient pathology at autopsy for a secondary neuropathologic diagnosis of AD), appear to contribute to cognitive impairment in LBD, and the combination is associated with a shorter interval between onset of motor symptoms and development of dementia and a shorter life span. Further, the co-occurrence of neocortical alpha-synuclein, tau and amyloid pathologies found at end-stage disease suggests a potential synergistic interaction of these individual pathologies in humans during life, mirroring experimental observations in animal and cell model systems that show how pathogenic species of synuclein fibrils can promote trans-synaptic spread of both tauopathy and synucleinopathy with strain-like properties. Newer post-mortem studies using digital methods to measure pathologic burden have highlighted distinct neocortical patterns of areas with relative higher density of tau pathology in LBD compared to AD that support these model data. The emerging field of cerebrospinal fluid and molecular imaging biomarkers of synuclein, amyloid and tau pathologies in LBD is contributing to a greater understanding of how the different pathologies evolve and interact to produce clinical heterogeneity in LBD. Future work to elucidate biologically meaningful clinical subgroups of synucleinopathy and its co-pathology must focus on the full clinicopathological spectrum of LBD and use validated biomarkers, when available, to design clinical trials based on the precise selection of homogeneous patient subgroups to maximize statistical power for detecting the impact of treatment.

References 124

1. 1.

   Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, (2015 ) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601.

   Not in our library10.1002/mds.26424

2. 2.

   Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, (2015 ) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30: 1600–1611.

   Not in our library10.1002/mds.26431

3. 3.

   Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P (2003 ) Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Arch Neurol 60: 387–392.

   Not in our library10.1001/archneur.60.3.387

4. 4.

   Halliday G, Hely M, Reid W, Morris J (2008 ) The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 115: 409–415.

   Not in our library10.1007/s00401-008-0344-8

5. 5.

   Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ (2010 ) Relationships between age and late progression of Parkinson’s disease: A clinico-pathological study. Brain 133: 1755–1762.

   Not in our library10.1093/brain/awq059

6. 6.

   Rosenthal E, Brennan L, Xie S, Hurtig H, Milber J, (2010 ) Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 25: 1170–1176.

   Not in our library10.1002/mds.23073

7. 7.

   Hamilton RL (2000 ) Lewy bodies in Alzheimer’s disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10: 378–384.

   Not in our library10.1111/j.1750-3639.2000.tb00269.x

8. 8.

   Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, (2007 ) DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68: 812–819.

   Not in our library10.1212/01.wnl.0000256715.13907.d3

9. 9.

   McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, (1996 ) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47: 1113–1124.

   Not in our library10.1212/wnl.47.5.1113

10. 10.

    Feiler MS, Strobel B, Freischmidt A, Helferich AM, Kappel J, (2015 ) TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol 211: 897–911.

    Not in our library10.1083/jcb.201504057

11. 11.

    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, (2005 ) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863–1872.

    Not in our library10.1212/01.wnl.0000187889.17253.b1

12. 12.

    Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, (2016 ) Arguing against the proposed definition changes of PD. Mov Disorders: official journal of the Mov Disord 31: 1619–1622.

    Not in our library10.1002/mds.26721

13. 13.

    Irwin DJ, Grossman M, Weintraub D, Hurtig HW, Duda JE, (2017 ) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis. Lancet Neurol 16: 55–65.

    Not in our library10.1016/s1474-4422(16)30291-5

14. 14.

    Ballard C, Ziabreva I, Perry R, Larsen JP, O’Brien J, (2006 ) Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67: 1931–1934.

    Not in our library10.1212/01.wnl.0000249130.63615.cc

15. 15.

    Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, (2013 ) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 70: 727–735.

    Not in our library10.1001/jamaneurol.2013.1925

16. 16.

    Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, (2009 ) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361: 1651–1661.

    Not in our library10.1056/nejmoa0901281

17. 17.

    Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, (2012 ) GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79: 1944–1950.

    Not in our library10.1212/wnl.0b013e3182735e9a

18. 18.

    Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, (2013 ) APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70: 223–228.

    Not in our library10.1001/jamaneurol.2013.600

19. 19.

    Boeve BF, Silber MH, Ferman TJ, Kokmen E, Smith GE, (1998 ) REM sleep behavior disorder and degenerative dementia: An association likely reflecting Lewy body disease. Neurology 51: 363–370.

    Not in our library10.1212/wnl.51.2.363

20. 20.

    Jacobs ML, Dauvilliers Y, St Louis EK, McCarter SJ, Romenets SR, (2016 ) Risk factor profile in Parkinson’s disease subtype with REM sleep behavior disorder. J Parkinsons Dis 6: 231–237.

    Not in our library10.3233/jpd-150725

21. 21.

    Boeve BF, Dickson DW, Olson EJ, Shepard JW, Silber MH, (2007 ) Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 8: 60–64.

    Not in our library10.1016/j.sleep.2006.08.017

22. 22.

    Irwin DJ, Lee VM, Trojanowski JQ (2013 ) Parkinson’s disease dementia: Convergence of α-synuclein, tau and amyloid-βpathologies. Nat Rev Neurosci 14: 626–636.

    Not in our library10.1038/nrn3549

23. 23.

    Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, (2012 ) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72: 587–598.

    Not in our library10.1002/ana.23659

24. 24.

    Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008 ) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23: 837–844.

    Not in our library10.1002/mds.21956

25. 25.

    Coughlin D, Xie X, Liang M (2018 ) Clinical and pathological influences of tau pathology in lewy body disorders. Under review.

    Not in our library10.1002/ana.25392

26. 26.

    Selikhova M1, Williams DR, Kempster PA, Holton JL, Revesz T, (2009 ) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132: 2947–2957.

    Not in our library10.1093/brain/awp234

27. 27.

    Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB (2017 ) Clinical criteria for subtyping Parkinson’s disease: Biomarkers and longitudinal progression. Brain 140: 1959–1976.

    Not in our library10.1093/brain/awx118

28. 28.

    Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, (2008 ) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71: 670–676.

    Not in our library10.1212/01.wnl.0000324625.00404.15

29. 29.

    Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, (1997 ) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276: 2045–2047.

    Not in our library10.1126/science.276.5321.2045

30. 30.

    Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, (1997 ) Alpha-synuclein in Lewy bodies. Nature 388: 839–840.

    Not in our library10.1038/42166

31. 31.

    Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, (2003 ) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24: 197–211.

    Not in our library10.1016/s0197-4580(02)00065-9

32. 32.

    Jellinger KA (2008 ) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116: 1–16.

    Not in our library10.1007/s00401-008-0406-y

33. 33.

    Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, (2008 ) Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 18: 220–224.

    Not in our library10.1111/j.1750-3639.2007.00117.x

34. 34.

    Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, (2004 ) Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 63: 742–749.

    Not in our library10.1093/jnen/63.7.742

35. 35.

    Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, (2009 ) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117: 613–634.

    Not in our library10.1007/s00401-009-0538-8

36. 36.

    Parkkinen L, Kauppinen T, Pirttilä T, Autere JM, Alafuzoff I (2005 ) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57: 82–91.

    Not in our library10.1002/ana.20321

37. 37.

    Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, (2008 ) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115: 437–444.

    Not in our library10.1007/s00401-008-0345-7

38. 38.

    Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, (2012 ) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338: 949–953.

    Not in our library10.1126/science.1227157

39. 39.

    Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, (2012 ) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209: 975–986.

    Not in our library10.1084/jem.20112457

40. 40.

    Luk KC, Song C, O’Brien P, Stieber A, Branch JR, (2009 ) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 106: 20051–20056.

    Not in our library10.1073/pnas.0908005106

Cited by papers we hold 1

• Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.